Our Patients

Our Promise to Patients

At CSL we are Driven by Our Promise and guided by our Values: Patient Focus, Innovation, Integrity, Collaboration and Superior Performance.

CSL is committed to putting the patient first in all that we do to discover, develop, and deliver biotherapeutics and vaccines that meet their needs.

We know that every patient is someone’s child, parent, grandparent, family member, friend or colleague. We also understand that rare and serious diseases impact more than just the patient. They also impact their loved ones and the communities that support them.

With that in mind, we strive to deliver therapeutics that meet patient needs, as well as build support systems to create empowerment and community through various programs and activities around the world. We also partner with patient advocacy organizations to improve and expand outreach, education and access to medicines and resources.

Our patients are our passion and that drives the way we work. We are committed to full transparency of expectations and outcomes when partnering with them. We listen closely to patients about their experiences and collaborate with them from early research through the delivery of our innovative medicines. We seek to fully understand their challenges to ensure our research is relevant, meaningful and leads to therapies that result in outcomes that are important to them and make a difference in their lives.

Our people are the heart of our Patient Focus culture and we strive to earn our patients’ trust every day. CSL employees understand that they are personally accountable for ensuring our interactions with patients are responsible, respectful and humble. We recognize patients as the experts in how diseases impact their lives and we actively seek their insights to guide our efforts.

The commitment of our people to Patient Focus as part of our Values-based culture is essential to delivering on our promise to patients and improving public health.

COVID-19: A Message from Our CEO

"As the COVID-19 pandemic evolves, CSL remains committed to safeguarding our patients, our donors and our people. In keeping with our values-based culture, CSL has taken precautions to ensure our employees and our facilities remain safe so we can continue to deliver on our promise to patients and public health." - Paul Perreault, CEO & Managing Director, CSL Limited

Read More About CSL Behring's Efforts with COVID-19

How can we help you?

Immunodeficiency & Autoimmune Diseases

We offer one of the most comprehensive portfolios of high-quality, technically advanced immunoglobulin (Ig) therapies and we are the leading Ig manufacturer in the world. Treatments are available for the following conditions:

Within the United States:
- Primary Immunodeficiency
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Idiopathic Thrombocytopenic Purpura (ITP)

Outside the United States:
- Primary Immunodeficiency
- Secondary Immunodeficiency (SID)
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Idiopathic Thrombocytopenic Purpura (ITP)
- Kawasaki Disease (KD)
- Guillain-Barré Syndrome (GBS)

Hereditary Bleeding Disorders

We are a world leader in innovative medicines for the treatment of bleeding disorders. We offer the largest portfolio for the treatment of hereditary bleeding disorders with more than a dozen plasma-derived and recombinant coagulation factor concentrates. Treatments are available for the following conditions:

Within the United States:
- Hemophilia A
- Hemophilia B
- von Willebrand Disease
- Factor XIII Deficiency
- Fibrinogen Deficiency

Outside the United States:
- Hemophilia A
- Hemophilia B
- von Willebrand Disease
- Factor XIII Deficiency
- Fibrinogen Deficiency
- Factor X Deficiency

Hereditary Angioedema (HAE)

We introduced the world's first subcutaneous preventative treatment for attacks of Hereditary Angioedema (HAE), while still offering our intravenous C1-esterase inhibitor therapy for on-demand treatment.

Alpha 1 Antitrypsin Deficiency

Our Alpha 1 Antitrypsin treats Alpha 1 Antitrypsin Deficiency (AATD) in patients with AATD-related emphysema.

Find a Clinical Trial

A clinical trial is a research study that is done to find out if medical treatments can improve people’s health. A medical treatment can be a drug, medical device, medical procedure, or a change in a person’s behavior such as diet or exercise. People who take part in clinical trials are volunteers. They are also called “participants."

Therapeutic Area	Condition	Study Number	Description	Status ^{(Click on link to learn more)}
Haematology and Thrombosis	Hemophilia B	CSL654_3003	A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B	Active, Not Recruiting
	Reversal of acquired coagulation factor deficiency	BE1116_4001	An Observational Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra^® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding	Recruiting
	Sickle Cell	CSL200_1001	CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease	Active, Not Recruiting
	Sickle Cell	CSL889_1001	A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease	Recruiting
Cardiovascular and Metabolic	Acute Coronary Syndrome	CSL112_3001	Study to investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)	Recruiting
	Diabetic Kidney Disease	CSL346_2001	A Phase 2a Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease	Recruiting
Immunology and Neurology	Dermatomyositis (DM)	IgPro20_3007	A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with Dermatomyositis (DM)	Recruiting
	Pediatric CIDP	IgPro10_4002	Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP	Recruiting
	Hereditary Angioedema (HAE)	CSL312_2001	A study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)	Active, Not Recruiting
	Hereditary Angioedema (HAE)	CSL830_3003	A Phase 3 study to evaluate clinical efficacy, safety, and pharmacokineti00cs of subcutaneous administration of human plasma derived C1-esterase inhibitor in the prophylactic treatment of hereditary angioedema in Japanese subjects	Recruiting
	Hidradenitis Suppurativa and Palmoplantar Pustulosis	CSL324_1002	A study of the safety and pharmacokinetics of repeat doses of CSL324 in subjects with hidradenitis suppurativa and palmoplantar pustulosis	Recruiting
	Systemic Sclerosis	IgPro20_2001	A study to investigate the safety, tolerability, and pharmacokinetics of IgPro20 in subjects with diffuse cutaneous systemic sclerosis (dcSSc)	Recruiting
	Healthy Subjects	CSL324_1003	Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects	Recruiting
	Healthy Subjects	CSL730_1002	A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects	Recruiting
Respiratory	Mild Asthma	CSL311_1001	A Clinical Study to test the safety, exposure, and markers of Efficacy of CSL311 in patients with mild asthma.	Recruiting
	alpha-1 antitrypsin deficiency	AmAREtTI Study	Respreeza® Self-administration and Learning Program (AmAREtTI Study- Auto-Administration de Respreeza® et Programme d'apprenTIssage)	Recruiting
Transplant	Antibody-mediated kidney transplant rejection	CSL300_3001	A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients	Recruiting
	Acute GVHD (aGVHD)	CSL964_2001	The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE)	Recruiting
	Graft Versus Host Disease (GVHD)	CSL964_5001	A study on the efficacy of AAT with corticosteroids compared with corticosteroids alone as first line therapy for patients with high-risk acute GVHD	Recruiting
COMPLETED STUDIES:
COVID 19	COVID-19	CSL312_COVID-19	A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)	Completed
	COVID-19	CSL324_COVID-19	CSL324 in COVID-19	Withdrawn
Haematology and Thrombosis	Congenital Fibrinogen Deficiency	BI3023_4003	An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency	Completed
	Hemophilia A	CSL627_3001	An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A	Completed
	Von Willebrand Disease	CSLCT-BIO-12-83	Study of Voncento^® in Subjects With Von Willebrand Disease	Completed
Cardiovascular and Metabolic	Coronary Heart Disease	CSL112_1001	Assessing the pharmacokinetics, safety, and tolerability of CSL112 in healthy Japanese and Caucasian adults	Completed
	Renal Impairment and Acute Myocardial Infarction	CSL112_2001	A Phase 2 Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Moderate Renal Impairment and Acute Myocardial Infarction	Results
Immunology and Neurology	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	IgPro20_3004	Extension Study of Maintenance Treatment with Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Results
	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	IgPro10_5004	Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP (HELIPAD 1)	Completed
	HIV-1	CAL-USA-11	An Adaptive Phase I/II Study of the Safety of CAL-USA-11 in HIV-1 Infected Adults Previously Exposed to ART	Results
	Primary Immune Deficiency (PID)	IgPro20_1001	Comparison of 2 Infusion Devices With Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra: An Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump	Results
	Primary Immune Deficiency (PID)	IgPro20_4004	Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra^®) in Subjects With Primary Immunodeficiency (PID)	Results
	Primary Immune Deficiency (PID)	IgPro20_4005	Study of Immune Deficiency Patients treated with Subcutaneous Immunoglobulin (IgPro20, Hizentra^®) on Weekly and Biweekly Schedules	Results
	Systemic Sclerosis	IgPro10_2001	Efficacy and safety study of IgPro10 in adults with Systemic Sclerosis	Withdrawn
	Healthy Subjects	CSL324_1001	Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults	Completed
	Healthy Subjects	CSL730_1001	Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults	Cancelled
Transplant	Antibody-mediated kidney transplant rejection	CSL842_3001	Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients	Cancelled

Participate in a Clinical Trial

Discover what is involved in participating in one of our clinical trials and how you can enroll.

Learn More